Prolor Biotech Announces Positive Results of Obesity/Diabetes Drug Candidate

Prolor Biotech reported positive preclinical results from a study of its long-acting obesity/Type II diabetes drug candidate MOD-6030. The study was designed to measure the potential therapeutic effect of MOD-6030 injected once weekly as measured by weight loss, reduction in food intake, glycemic control and cholesterol levels.
The Sacramento Bee